BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing proprietary drug delivery technologies to develop and commercialize novel prescription, over-the-counter and supplement products that address large markets in dermatology and women’s health. The Company’s objective is to develop products that treat health or age-related conditions that are not presently being addressed or treated at all or are currently treated with drug therapies or drug delivery approaches that are sub-optimal. BioPharmX has developed a product portfolio using its drug delivery technologies, including delivery mechanisms for antibiotics, biologic materials, and molecular iodine.

The Company currently has one marketed product, a VI2OLET iodine dietary supplement, two clinical‑stage product candidates, BPX01 and BPX03 and one development‑stage product candidate, BPX02. VI2OLET is a molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches, and swelling. BPX03 is a prescription drug version of the molecular iodine tablet for the treatment of moderate to severe, periodic breast pain associated with FBC and cyclic mastalgia. BPX01 is a hydrophilic, topical antibiotic gel for the treatment of acne vulgaris and BPX02 is an injectable product utilizing biologic materials for aesthetic dermatology applications.


Show more
Type
Public
HQ
Menlo Park, US
Founded
2011
Size (employees)
20 (est)
BioPharmX was founded in 2011 and is headquartered in Menlo Park, US
Report incorrect company information

BioPharmX Office Locations

BioPharmX has an office in Menlo Park
Menlo Park, US (HQ)
d 1505 Adams Dr
Show all (1)
Report incorrect company information

BioPharmX Financials and Metrics

BioPharmX Financials

BioPharmX 's revenue was reported to be $73 k in FY, 2018
USD

Revenue (Q1, 2019)

18 k

Gross profit (Q1, 2019)

11 k

Gross profit margin (Q1, 2019), %

61.1%

EBIT (Q1, 2019)

(4.4 m)

Market capitalization (22-Jun-2018)

44.5 m

Closing share price (22-Jun-2018)

0.2

Cash (30-Apr-2018)

10.9 m
BioPharmX 's current market capitalization is $44.5 m.
Annual
USDFY, 2017FY, 2018

Revenue

100 k73 k

Cost of goods sold

516 k250 k

Gross profit

(416 k)(177 k)

Gross profit Margin, %

(416%)(242%)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018Q1, 2019

Revenue

5 k20 k33 k19 k33 k19 k18 k18 k

Cost of goods sold

10 k19 k20 k17 k28 k11 k8 k7 k

Gross profit

(5 k)1 k13 k2 k5 k8 k10 k11 k

Gross profit Margin, %

(100%)5%39%11%15%42%56%61%
Annual
USDFY, 2017FY, 2018

Cash

6.5 m7.6 m

Accounts Receivable

4 k7 k

Inventories

38 k10 k

Current Assets

6.8 m8 m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018Q1, 2019

Cash

7.4 m2.2 m4 m436 k468 k6.7 m1.6 m10.9 m

Accounts Receivable

33 k9 k6 k1 k7 k3 k8 k5 k

Inventories

364 k336 k76 k112 k77 k30 k15 k6 k

Current Assets

8.2 m2.8 m4.4 m1 m1.3 m7 m2.2 m11.3 m
Annual
USDFY, 2017FY, 2018

Net Income

(18.4 m)(16.6 m)

Depreciation and Amortization

141 k52 k

Inventories

62 k28 k

Accounts Payable

774 k(1.2 m)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2019

Net Income

(4.4 m)

Depreciation and Amortization

16 k

Inventories

364 k336 k76 k112 k77 k30 k4 k

Accounts Payable

3.3 m1.8 m2.4 m3.4 m2.8 m2.3 m416 k
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

BioPharmX Online and Social Media Presence

Embed Graph
Report incorrect company information